
## Mahmoud Reza Jaafari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7197473/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MicroRNA: A novel target of curcumin in cancer therapy. Journal of Cellular Physiology, 2018, 233, 3004-3015.	4.1	192
2	Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. International Journal of Nanomedicine, 2018, Volume 13, 7727-7747.	6.7	181
3	Perspective of Fe <sub>3</sub> O <sub>4</sub> Nanoparticles Role in Biomedical Applications. Biochemistry Research International, 2016, 2016, 1-32.	3.3	163
4	MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. European Journal of Cancer, 2016, 53, 25-32.	2.8	159
5	Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. Journal of Controlled Release, 2015, 220, 275-286.	9.9	152
6	MicroRNA: Relevance to stroke diagnosis, prognosis, and therapy. Journal of Cellular Physiology, 2018, 233, 856-865.	4.1	147
7	Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers. Current Pharmaceutical Design, 2016, 22, 5257-5269.	1.9	129
8	CD47: role in the immune system and application to cancer therapy. Cellular Oncology (Dordrecht), 2020, 43, 19-30.	4.4	114
9	Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies. Current Cancer Drug Targets, 2016, 16, 773-788.	1.6	111
10	Diagnostic and Therapeutic Potential of Exosomes in Cancer: The Beginning of a New Tale?. Journal of Cellular Physiology, 2017, 232, 3251-3260.	4.1	107
11	Toxicity assessment of superparamagnetic iron oxide nanoparticles in different tissues. Artificial Cells, Nanomedicine and Biotechnology, 2020, 48, 443-451.	2.8	105
12	Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice. PLoS ONE, 2015, 10, e0142563.	2.5	102
13	The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna Journal of Phytomedicine, 2016, 6, 567-577.	0.2	99
14	Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. Journal of Cellular Physiology, 2018, 233, 2949-2965.	4.1	98
15	Docetaxel-Loaded Solid Lipid Nanoparticles: Preparation, Characterization, In Vitro, and In Vivo Evaluations. Journal of Pharmaceutical Sciences, 2013, 102, 1994-2004.	3.3	93
16	Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. Neurotherapeutics, 2018, 15, 430-438.	4.4	90
17	Therapeutic application of multipotent stem cells. Journal of Cellular Physiology, 2018, 233, 2815-2823.	4.1	90
18	Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 248-258.	4.3	87

#	Article	IF	CITATIONS
19	Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents. Current Medicinal Chemistry, 2016, 23, 455-463.	2.4	86
20	Oral nanoâ€curcumin formulation efficacy in management of mild to moderate hospitalized <scp>coronavirus disease</scp> â€19 patients: An open label nonrandomized clinical trial. Phytotherapy Research, 2021, 35, 2616-2623.	5.8	86
21	Boron neutron capture therapy: Moving toward targeted cancer therapy. Journal of Cancer Research and Therapeutics, 2016, 12, 520.	0.9	83
22	The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine, 2007, 25, 6107-6117.	3.8	82
23	State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. Journal of Cellular Physiology, 2018, 233, 888-900.	4.1	82
24	Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Journal of Controlled Release, 2015, 220, 308-315.	9.9	69
25	Effect of Topical Liposomes Containing Paromomycin Sulfate in the Course of <i>Leishmania major</i> Infection in Susceptible BALB/c Mice. Antimicrobial Agents and Chemotherapy, 2009, 53, 2259-2265.	3.2	68
26	Micro and nanotechnologies for bone regeneration: Recent advances and emerging designs. Journal of Controlled Release, 2018, 274, 35-55.	9.9	68
27	Redox-sensitive nanoscale drug delivery systems for cancer treatment. International Journal of Pharmaceutics, 2020, 589, 119882.	5.2	65
28	lmmune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine, 2006, 24, 5708-5717.	3.8	64
29	Fabrication of hybrid scaffold based on hydroxyapatite-biodegradable nanofibers incorporated with liposomal formulation of BMP-2 peptide for bone tissue engineering. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1987-1997.	3.3	64
30	Mesenchymal stem cells: A new platform for targeting suicide genes in cancer. Journal of Cellular Physiology, 2018, 233, 3831-3845.	4.1	63
31	Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Colloids and Surfaces B: Biointerfaces, 2016, 139, 228-236.	5.0	62
32	Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine. International Journal of Biological Macromolecules, 2020, 156, 1455-1463.	7.5	62
33	Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. Journal of Cosmetic Dermatology, 2015, 14, 174-177.	1.6	59
34	Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation. Journal of Controlled Release, 2017, 264, 228-236.	9.9	59
35	P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Letters, 2014, 355, 54-60.	7.2	58
36	Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunology Letters, 2014, 162, 87-93.	2.5	58

#	Article	IF	CITATIONS
37	A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy. International Journal of Pharmaceutics, 2018, 551, 300-308.	5.2	58
38	MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. Journal of Controlled Release, 2019, 303, 223-236.	9.9	58
39	Delivery of LNA-antimiR-142-3p by Mesenchymal Stem Cells-Derived Exosomes to Breast Cancer Stem Cells Reduces Tumorigenicity. Stem Cell Reviews and Reports, 2020, 16, 541-556.	3.8	58
40	Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. European Journal of Pharmaceutical Sciences, 2016, 86, 125-135.	4.0	55
41	Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy. Scientific Reports, 2020, 10, 5569.	3.3	54
42	OralÂadministration of nanomicelle curcumin in the prevention of radiotherapyâ€induced mucositis in head and neck cancers. Special Care in Dentistry, 2019, 39, 166-172.	0.8	53
43	A tripleâ€blind, placeboâ€controlled, randomized clinical trial to evaluate the effect of curcuminâ€containing nanomicelles on cellular immune responses subtypes and clinical outcome in <scp>COVID</scp> â€19 patients. Phytotherapy Research, 2021, 35, 6417-6427.	5.8	52
44	Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma. Nanoscale Research Letters, 2020, 15, 101.	5.7	52
45	Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. Atherosclerosis, 2019, 283, 69-78.	0.8	49
46	Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma. Scientific Reports, 2019, 9, 9527.	3.3	47
47	Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2671-2682.	3.3	46
48	Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: In vitro and in vivo anti-tumor study. International Journal of Pharmaceutics, 2020, 580, 119211.	5.2	46
49	Antifungal activity of essential oil-loaded solid lipid nanoparticles condition. Iranian Journal of Basic Medical Sciences, 2016, 19, 1231-1237.	1.0	46
50	Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. PLoS ONE, 2017, 12, e0185099.	2.5	45
51	Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iranian Journal of Basic Medical Sciences, 2019, 22, 282-289.	1.0	44
52	Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. International Journal of Pharmaceutics, 2015, 495, 162-170.	5.2	43
53	Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Expert Opinion on Drug Delivery, 2016, 13, 325-336.	5.0	41
54	Folate targeted PEGylated liposomes for the oral delivery of insulin: In vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces, 2020, 194, 111203.	5.0	41

#	Article	IF	CITATIONS
55	Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers. European Journal of Pharmaceutical Sciences, 2018, 119, 159-170.	4.0	40
56	A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. Journal of Drug Targeting, 2018, 26, 365-372.	4.4	40
57	Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization. Journal of Cellular Biochemistry, 2018, 119, 4251-4264.	2.6	39
58	Antitumor effects of curcumin: A lipid perspective. Journal of Cellular Physiology, 2019, 234, 14743-14758.	4.1	39
59	Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis. Pathology Research and Practice, 2020, 216, 153082.	2.3	39
60	PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. Archives of Medical Science, 2021, 17, 1365-1377.	0.9	39
61	Effects of immunization against PCSK9 in an experimental model of breast cancer. Archives of Medical Science, 2019, 15, 570-579.	0.9	37
62	A review on liposome-based therapeutic approaches against malignant melanoma. International Journal of Pharmaceutics, 2021, 599, 120413.	5.2	37
63	Safranal-loaded solid lipid nanoparticles: evaluation of sunscreen and moisturizing potential for topical applications. Iranian Journal of Basic Medical Sciences, 2015, 18, 58-63.	1.0	36
64	Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 104, 42-50.	4.3	35
65	Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice. Acta Tropica, 2019, 196, 142-149.	2.0	35
66	Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer. European Journal of Cancer, 2020, 129, 80-96.	2.8	35
67	The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. International Journal of Pharmaceutics, 2014, 473, 326-333.	5.2	34
68	Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes upon Mild Hyperthermia in C26 Tumor Bearing BALB/c Mice. Molecular Pharmaceutics, 2017, 14, 712-721.	4.6	33
69	Preparation, characterization, and optimization of auraptene-loaded solid lipid nanoparticles as a natural anti-inflammatory agent: In vivo and in vitro evaluations. Colloids and Surfaces B: Biointerfaces, 2018, 164, 332-339.	5.0	33
70	Tumorâ€associated macrophages and epithelial–mesenchymal transition in cancer: Nanotechnology comes into view. Journal of Cellular Physiology, 2018, 233, 9223-9236.	4.1	33
71	Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. International Journal of Pharmaceutics, 2016, 505, 89-95.	5.2	31
72	Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunology Letters, 2016, 176, 57-64.	2.5	31

#	Article	IF	CITATIONS
73	Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 156-165.	3.4	31
74	The protective activity of nanomicelle curcumin in bisphenol Aâ€induced cardiotoxicity following subacute exposure in rats. Environmental Toxicology, 2019, 34, 319-329.	4.0	31
75	The Effect of Nanocurcumin in Improvement of Knee Osteoarthritis: A Randomized Clinical Trial. Current Rheumatology Reviews, 2020, 16, 158-164.	0.8	31
76	Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunologic Research, 2018, 66, 200-206.	2.9	30
77	Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies. Colloids and Surfaces B: Biointerfaces, 2015, 136, 885-891.	5.0	29
78	Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Immunology Letters, 2017, 190, 108-117.	2.5	29
79	Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer. Archives of Medical Science, 2019, 15, 559-569.	0.9	29
80	P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 664-672.	2.8	29
81	Electrospun Doxorubicin-loaded PEO/PCL core/sheath nanofibers for chemopreventive action against breast cancer cells. Journal of Drug Delivery Science and Technology, 2021, 64, 102576.	3.0	29
82	The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations. Pharmaceutical Research, 2017, 34, 1849-1856.	3.5	28
83	Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy. Life Sciences, 2020, 252, 117646.	4.3	28
84	Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis. Experimental Parasitology, 2014, 146, 78-86.	1.2	27
85	Solubilization Behavior of Polyene Antibiotics in Nanomicellar System: Insights from Molecular Dynamics Simulation of the Amphotericin B and Nystatin Interactions with Polysorbate 80. Molecules, 2016, 21, 6.	3.8	26
86	Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. International Journal of Pharmaceutics, 2016, 511, 236-244.	5.2	26
87	Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives. Journal of Cellular Physiology, 2019, 234, 2329-2336.	4.1	26
88	The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 876.	1.6	26
89	Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma. Colloids and Surfaces B: Biointerfaces, 2021, 200, 111589.	5.0	26
90	Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Letters, 2018, 424, 109-116.	7.2	25

#	Article	IF	CITATIONS
91	The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice. Experimental Parasitology, 2019, 200, 30-35.	1.2	25
92	Endogenous stimuli-responsive linkers in nanoliposomal systems for cancer drug targeting. International Journal of Pharmaceutics, 2019, 572, 118716.	5.2	25
93	Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102150.	3.3	25
94	Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide. Journal of Drug Targeting, 2021, 29, 617-630.	4.4	25
95	Preparation, characterization and evaluation of moisturizing and UV protecting effects of topical solid lipid nanoparticles. Brazilian Journal of Pharmaceutical Sciences, 2012, 48, 683-690.	1.2	24
96	PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells. Nanomedicine, 2017, 12, 1475-1490.	3.3	24
97	Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: <i>in vitro</i> and <i>in vivo</i> studies. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 594-606.	2.8	24
98	Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Scientific Reports, 2019, 9, 2221.	3.3	24
99	Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates. Vaccines, 2021, 9, 749.	4.4	24
100	Deciphering biological characteristics of tumorigenic subpopulations in human colorectal cancer reveals cellular plasticity. Journal of Research in Medical Sciences, 2016, 21, 64.	0.9	24
101	Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. European Journal of Pharmaceutical Sciences, 2015, 80, 66-73.	4.0	23
102	Radio frequency hyperthermia of cancerous cells with gold nanoclusters: an in vitro investigation. Gold Bulletin, 2017, 50, 43-50.	2.4	23
103	BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers. International Journal of Pharmaceutics, 2019, 564, 77-89.	5.2	23
104	Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer. Iranian Journal of Pharmaceutical Research, 2014, 13, 15-25.	0.5	23
105	Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-16.	1.2	23
106	Combination Therapy with 1% Nanocurcumin Gel and 0.1% Triamcinolone Acetonide Mouth Rinse for Oral Lichen Planus: A Randomized Double-Blind Placebo Controlled Clinical Trial. Dermatology Research and Practice, 2020, 2020, 1-7.	0.8	22
107	Liposomal adjuvant development for leishmaniasis vaccines. Therapeutic Advances in Vaccines, 2017, 5, 85-101.	2.7	21
108	Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study. International Journal of Pharmaceutics, 2019, 567, 118492.	5.2	21

#	Article	IF	CITATIONS
109	Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102013.	3.3	21
110	Biomaterials in Valvular Heart Diseases. Frontiers in Bioengineering and Biotechnology, 2020, 8, 529244.	4.1	20
111	Spectrofluorometric Method Development and Validation for the Determination of Curcumin in Nanoliposomes and Plasma. Journal of Fluorescence, 2020, 30, 1113-1119.	2.5	20
112	Topical application of curcumin regulates the angiogenesis in diabetic <b>â€</b> impaired cutaneous wound. Cell Biochemistry and Function, 2020, 38, 558-566.	2.9	20
113	Biodistribution and <i>In Vivo</i> Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl- <i>sn</i> -Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	19
114	A fires novel report of exosomal electrochemical sensor for sensing micro RNAs by using multi covalent attachment p19 with high sensitivity. Biosensors and Bioelectronics, 2018, 113, 74-81.	10.1	19
115	Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor. Colloids and Surfaces B: Biointerfaces, 2018, 164, 107-115.	5.0	19
116	Regulation of in vivo behavior of TAT-modified liposome by associated protein corona and avidity to tumor cells. International Journal of Nanomedicine, 2018, Volume 13, 7441-7455.	6.7	19
117	Targetedâ€nanoliposomal combretastatin A4 (CAâ€4) as an efficient antivascular candidate in the metastatic cancer treatment. Journal of Cellular Physiology, 2019, 234, 14721-14733.	4.1	19
118	Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: In vitro and in vivo studies in a colon cancer mouse model. Life Sciences, 2021, 264, 118605.	4.3	19
119	Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy. Scientific Reports, 2021, 11, 14661.	3.3	19
120	Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iranian Journal of Basic Medical Sciences, 2015, 18, 385-92.	1.0	19
121	Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model. International Journal of Pharmaceutics, 2022, 613, 121396.	5.2	19
122	Preparation, characterization and molecular modeling of PEGylated human growth hormone with agonist activity. International Journal of Biological Macromolecules, 2015, 80, 400-409.	7.5	18
123	Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 370-377.	2.8	18
124	Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art. Drug Discovery Today, 2019, 24, 1116-1131.	6.4	18
125	<p>Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy</p> . International Journal of Nanomedicine, 2020, Volume 15, 5279-5288.	6.7	18
126	The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma. Biochimie, 2020, 176, 21-30.	2.6	18

Mahmoud Reza Jaafari

#	Article	IF	CITATIONS
127	Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model. Immunobiology, 2018, 223, 493-500.	1.9	17
128	Reducing Doxorubicin resistance in breast cancer by liposomal FOXM1 aptamer: In vitro and in vivo. Life Sciences, 2020, 262, 118520.	4.3	17
129	Effects of immunisation against PCSK9 in mice bearing melanoma. Archives of Medical Science, 2020, 16, 189-199.	0.9	17
130	Immunoregulatory, proliferative and anti-oxidant effects of nanocurcuminoids on adipose-derived mesenchymal stem cells. EXCLI Journal, 2019, 18, 405-421.	0.7	17
131	<scp>Antiâ€</scp> epithelial cell adhesion molecule <scp>RNA</scp> aptamerâ€conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model. Biotechnology Progress, 2021, 37, e3116.	2.6	16
132	Liposome Circulation Time is Prolonged by CD47 Coating. Protein and Peptide Letters, 2020, 27, 1029-1037.	0.9	16
133	Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L. major dissemination to the spleen in BALB/c mice-based experimental setting. Acta Tropica, 2016, 159, 211-218.	2.0	15
134	Enhanced immune response induced by P5 HER2/neuâ€derived peptideâ€pulsed dendritic cells as a preventive cancer vaccine. Journal of Cellular and Molecular Medicine, 2018, 22, 558-567.	3.6	15
135	CD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives. Journal of Cellular Physiology, 2019, 234, 14622-14632.	4.1	15
136	Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma. Vaccine, 2020, 38, 5665-5677.	3.8	15
137	Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iranian Journal of Basic Medical Sciences, 2015, 18, 576-86.	1.0	15
138	Preparation of nanoliposomes linked to HER2/neuâ€derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. Journal of Cellular Biochemistry, 2019, 120, 1294-1303.	2.6	13
139	Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin. Expert Opinion on Drug Delivery, 2020, 17, 1049-1058.	5.0	13
140	B12-functionalized PEGylated liposomes for the oral delivery of insulin: In vitro and in vivo studies. Journal of Drug Delivery Science and Technology, 2022, 69, 103141.	3.0	13
141	Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma. Journal of Cosmetic Dermatology, 2019, 18, 870-873.	1.6	12
142	Secretory Expression of a Chimeric Peptide in Lactococcus lactis: Assessment of its Cytotoxic Activity and a Deep View on Its Interaction with Cell-Surface Glycosaminoglycans by Molecular Modeling. Probiotics and Antimicrobial Proteins, 2019, 11, 1034-1041.	3.9	12
143	<i>Ex vivo-</i> generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems. Immunotherapy, 2020, 12, 333-349.	2.0	12
144	The effect of UV radiation in the presence of TiO2-NPs on Leishmania major promastigotes. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129558.	2.4	12

Mahmoud Reza Jaafari

#	Article	IF	CITATIONS
145	Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and <scp>P5</scp> peptide: A novel vaccine for breast cancer. Biotechnology Progress, 2021, 37, e3095.	2.6	12
146	Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. Cancer Gene Therapy, 2022, 29, 814-824.	4.6	12
147	Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy. Life Sciences, 2022, 291, 120294.	4.3	12
148	New Oral Formulation and in Vitro Evaluation of Docetaxel-Loaded Nanomicelles. Molecules, 2016, 21, 1265.	3.8	11
149	Anionic nanoliposomes reduced atherosclerosis progression in Low Density Lipoprotein Receptor ( <i>LDLR</i> ) deficient mice fed a high fat diet. Journal of Cellular Physiology, 2018, 233, 6951-6964.	4.1	11
150	The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies. International Journal of Pharmaceutics, 2021, 604, 120710.	5.2	11
151	Targeting interleukinâ€Î² by plantâ€derived natural products: Implications for the treatment of atherosclerotic cardiovascular disease. Phytotherapy Research, 2021, 35, 5596-5622.	5.8	11
152	pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation. Journal of Pharmaceutical Sciences, 2021, 110, 3919-3928.	3.3	11
153	Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Current Drug Delivery, 2017, 14, 492-502.	1.6	11
154	Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS ONE, 2020, 15, e0243550.	2.5	11
155	Nanocarriers Call the Last Shot in the Treatment of Brain Cancers. Technology in Cancer Research and Treatment, 2022, 21, 153303382210809.	1.9	11
156	Evaluation of physicochemical and stability properties of human growth hormone upon enzymatic PEGylation. Journal of Applied Biomedicine, 2016, 14, 257-264.	1.7	10
157	The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble <i>Leishmania</i> antigen (SLA) encapsulated in nanoliposome. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 324-333.	2.8	10
158	The role of LPD-nanoparticles containing recombinant major surface glycoprotein of <i>Leishmania</i> (rgp63) in protection against leishmaniasis in murine model. Immunopharmacology and Immunotoxicology, 2018, 40, 72-82.	2.4	10
159	Improvement of the pharmacokinetic characteristics of liposomal doxorubicin using CD47 biomimickry. Journal of Pharmacy and Pharmacology, 2021, 73, 169-177.	2.4	10
160	The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 700-708.	1.7	10
161	Anti-inflammatory efficacy of Berberine Nanomicelle for improvement of cerebral ischemia: formulation, characterization and evaluation in bilateral common carotid artery occlusion rat model. BMC Pharmacology & Toxicology, 2021, 22, 54.	2.4	10
162	COMPARATIVE EFFICACY OF 1% CURCUMIN NANOMICELLE GEL AND 2% CURCUMIN GEL FOR TREATMENT OF RECURRENT APHTHOUS STOMATITIS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Journal of Evidence-based Dental Practice, 2022, , 101708.	1.5	10

#	Article	IF	CITATIONS
163	Supramolecular hybrid nanomaterials as drug delivery systems. Supramolecular Chemistry, 2011, 23, 411-418.	1.2	9
164	A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes. Colloids and Surfaces B: Biointerfaces, 2014, 122, 645-652.	5.0	9
165	Smart liposomal drug delivery for treatment of oxidative stress model in human embryonic stem cell-derived retinal pigment epithelial cells. International Journal of Pharmaceutics, 2018, 548, 62-72.	5.2	9
166	Nanoliposomal Encapsulation Enhances In Vivo Anti-Tumor Activity of Niclosamide against Melanoma. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 1618-1626.	1.7	9
167	Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis. Journal of Controlled Release, 2022, 343, 620-644.	9.9	9
168	Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia. Colloids and Surfaces B: Biointerfaces, 2015, 129, 71-78.	5.0	8
169	The impact of nanocarriers in the induction of antigen-specific immunotolerance in autoimmune diseases. Journal of Controlled Release, 2021, 339, 274-283.	9.9	8
170	Organ toxicity attenuation by nanomicelles containing curcuminoids: Comparing the protective effects on tissues oxidative damage induced by diazinon. Iranian Journal of Basic Medical Sciences, 2019, 22, 17-24.	1.0	8
171	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. Iranian Journal of Basic Medical Sciences, 2020, 23, 1065-1077.	1.0	7
172	Signal transducer and activator of transcription 3 downregulation in J774A.1 cell line as a model of M2 macrophages in tumor microenvironment. Journal of Cancer Research and Therapeutics, 2018, 14, 1121-1125.	0.9	7
173	Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides. Pharmaceutics, 2022, 14, 458.	4.5	7
174	Anti-Proliferative Potential of Fluorinated Curcumin Analogues: Experimental and Computational Analysis and Review of the Literature. Current Medicinal Chemistry, 2022, 29, 1459-1471.	2.4	6
175	Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures. Current Pharmaceutical Design, 2020, 25, 4883-4892.	1.9	6
176	Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 851-858.	1.7	6
177	Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 643-650.	1.7	6
178	AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer. Journal of Drug Delivery Science and Technology, 2022, 67, 102904.	3.0	6
179	Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects. Iranian Journal of Basic Medical Sciences, 2015, 18, 506-13.	1.0	6
180	Nano Liposomes Labeled with (99m)Tc-HMPAO, a Novel Agent for Blood Pool Imaging. Iranian Journal of Pharmaceutical Research, 2015, 14, 981-8.	0.5	6

#	Article	IF	CITATIONS
181	The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice. Iranian Journal of Basic Medical Sciences, 2016, 19, 178-86.	1.0	6
182	Anti-atherosclerosis effect of different doses of CETP vaccine in rabbit model of atherosclerosis. Biomedicine and Pharmacotherapy, 2016, 81, 468-473.	5.6	5
183	Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats. Journal of Diabetes Research, 2021, 2021, 1-11.	2.3	5
184	Vaccines targeting angiogenesis in melanoma. European Journal of Pharmacology, 2021, 912, 174565.	3.5	5
185	Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins. Iranian Journal of Pharmaceutical Research, 2016, 15, 573-81.	0.5	5
186	Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate. Reports of Biochemistry and Molecular Biology, 2019, 7, 156-166.	1.4	5
187	Safety Evaluation of Topical Application of Nano-Liposomal Form of Amphotericin B (SinaAmpholeish) on Healthy Volunteers: Phase I Clinical Trial. Iranian Journal of Parasitology, 2019, 14, 197-203.	0.6	5
188	Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 2379-2384.	1.7	4
189	Negatively-charged Liposome Nanoparticles Can Prevent Dyslipidemia and Atherosclerosis Progression in the Rabbit Model. Current Vascular Pharmacology, 2022, 20, 69-76.	1.7	4
190	Preventive cancer vaccination with P5 HER-2/neo-derived peptideâ€pulsed peripheral blood mononuclear cells in a mouse model of breast cancer. Biochemistry and Cell Biology, 2021, 99, 435-446.	2.0	4
191	Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model. International Immunopharmacology, 2021, 98, 107833.	3.8	4
192	Phosphatidylserine-containing liposomes: Therapeutic potentials against hypercholesterolemia and atherosclerosis. European Journal of Pharmacology, 2021, 908, 174308.	3.5	4
193	Development of a novel formulation method to prepare liposomal Epacadostat. European Journal of Pharmaceutical Sciences, 2021, 165, 105954.	4.0	4
194	Evaluation of the Anti-Tumor Activity of Niclosamide Nanoliposomes Against Colon Carcinoma. Current Molecular Pharmacology, 2020, 13, 245-250.	1.5	4
195	An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert Opinion on Drug Delivery, 2021, 18, 1795-1813.	5.0	4
196	Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (Sina Ampholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis. Journal of Arthropod-Borne Diseases, 2018, 12, 269-275.	0.9	4
197	Multi-successive-step pH sensitive procedure: Survey of dominant formation mechanism of therapeutic SPIONs. Ceramics International, 2019, 45, 6030-6036.	4.8	3
198	A simple and rapid-acting approach for the reduction of C-reactive protein. Biomedicine and Pharmacotherapy, 2019, 109, 2305-2308.	5.6	3

#	Article	IF	CITATIONS
199	Development of an effective liposomal cholesterol ester transfer protein (CETP) vaccine for protecting against atherosclerosis in rabbit model. Pharmaceutical Development and Technology, 2020, 25, 432-439.	2.4	3
200	Efficacy Comparison of TAT Peptide-Functionalized PEGylated Liposomal Doxorubicin in C26 and B16F0 Tumor Mice Models. International Journal of Peptide Research and Therapeutics, 2021, 27, 2099-2109.	1.9	3
201	In silico and In vitro Investigation of a Likely Pathway for Anti-Cancerous Effect of Thrombocidin-1 as a Novel Anticancer Peptide. Protein and Peptide Letters, 2020, 27, 751-762.	0.9	3
202	Improving potency of Nanoliposomal AE36 peptide vaccine by adding CD4+ T cell helper epitope and MPL in TUBO breast cancer mice model. Journal of Drug Delivery Science and Technology, 2022, 71, 103346.	3.0	3
203	A novel and easy to prepare azo-based bioreductive linker and its application in hypoxia-sensitive cationic liposomal doxorubicin: Synthesis, characterization, in vitro and in vivo studies in mice bearing C26 tumor. Chemistry and Physics of Lipids, 2022, 247, 105226.	3.2	3
204	A Phospholipase-A Activity in Soluble Leishmania Antigens Causes Instability of Liposomes. Current Drug Delivery, 2020, 17, 806-814.	1.6	2
205	Designing new nanoliposomal formulations and evaluating their effects on myeloidâ€derived suppressor cells and regulatory T cells in a colon cancer model aiming to develop an efficient delivery system for cancer treatment; an in vitro and in vivo study. Biotechnology and Applied Biochemistry, 2021	3.1	2
206	Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble Antigens. Iranian Journal of Parasitology, 2019, 14, 68-77.	0.6	2
207	Selective inhibitory effect of adenosine A1 receptor agonists on the proliferation of human tumor cell lines. Iranian Biomedical Journal, 2008, 12, 203-8.	0.7	2
208	Improvement of the Solubility Amphotericin B Using Olive Oil Nanoemulsion Coated with Chitosan for More Effective Treatment of Zoonotic Cutaneous Leishmaniasis Iranian Journal of Pharmaceutical Research, 2021, 20, 289-299.	0.5	2
209	Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica: study protocol for a randomized, controlled trial. Iranian Journal of Microbiology, 2021, 13, 718-723.	0.8	1
210	Study of the in vitro and in vivo antileishmanial activities of nimodipine in susceptible BALB/c mice. Journal of Vector Borne Diseases, 2020, 57, 78.	0.4	1
211	Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes. Journal of Pharmacy and Pharmacology, 0, , .	2.4	1
212	Antennapediaâ€derived positivelyâ€charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin. Biotechnology Progress, 2021, 37, e3202.	2.6	0
213	Multi-antigen vaccination with LPD nanoparticles containing rgp63 and rLmaC1N proteins induced effective immune response against leishmaniasis in animal model. Journal of Drug Delivery Science and Technology, 2021, 64, 102633.	3.0	0
214	A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis. Iranian Journal of Basic Medical Sciences, 2016, 19, 1345-1352.	1.0	0
215	Evaluation of leishmanicidal effect of extract by anti-leishmanial assay using promastigotes of. Avicenna Journal of Phytomedicine, 2018, 8, 524-532.	0.2	0
216	Sphingomyelin liposome bearing whole lysate antigens induce strong Th2 immune response in BALB/c mice. Iranian Journal of Basic Medical Sciences, 2021, 24, 222-231.	1.0	0